Jerald Radich

Summary

Affiliation: Fred Hutchinson Cancer Research Center
Country: USA

Publications

  1. ncbi request reprint Monitoring response to tyrosine kinase inhibitor therapy, mutational analysis, and new treatment options in chronic myelogenous leukemia
    Jerald P Radich
    Molecular Oncology Lab, Fred Hutchinson Cancer Research Center Seattle Cancer Care Alliance, Seattle, Washington 98109 1024, USA
    J Natl Compr Canc Netw 11:663-6. 2013
  2. pmc A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia
    Jerald P Radich
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 120:3898-905. 2012
  3. doi request reprint The biology of chronic myelogenous leukemia progression: who, what, where, and why?
    Jerald P Radich
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Hematol Oncol Clin North Am 25:967-80, v. 2011
  4. doi request reprint Measuring response to BCR-ABL inhibitors in chronic myeloid leukemia
    Jerald P Radich
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Cancer 118:300-11. 2012
  5. doi request reprint Chronic myeloid leukemia 2010: where are we now and where can we go?
    Jerald P Radich
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Hematology Am Soc Hematol Educ Program 2010:122-8. 2010
  6. ncbi request reprint HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen
    Jerald P Radich
    Clinical Research Division, Fred Hutchinson Cancer Research Center, D4 100, 1100 Fairview Ave N, Seattle, WA 98109, USA
    Blood 102:31-5. 2003
  7. pmc Gene expression changes associated with progression and response in chronic myeloid leukemia
    Jerald P Radich
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Proc Natl Acad Sci U S A 103:2794-9. 2006
  8. ncbi request reprint Individual-specific variation of gene expression in peripheral blood leukocytes
    Jerald P Radich
    Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, D4 100, Seattle, WA 98109, USA
    Genomics 83:980-8. 2004
  9. ncbi request reprint Monitoring chronic myelogenous leukemia in the age of tyrosine kinase inhibitors
    Jerald P Radich
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, Seattle, WA 98109, USA
    J Natl Compr Canc Netw 5:497-504. 2007
  10. doi request reprint Molecular monitoring of patients with chronic myeloid leukemia: clinical examples from a non-trial setting
    Jerald P Radich
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Clin Lymphoma Myeloma 9:S391-4. 2009

Detail Information

Publications88

  1. ncbi request reprint Monitoring response to tyrosine kinase inhibitor therapy, mutational analysis, and new treatment options in chronic myelogenous leukemia
    Jerald P Radich
    Molecular Oncology Lab, Fred Hutchinson Cancer Research Center Seattle Cancer Care Alliance, Seattle, Washington 98109 1024, USA
    J Natl Compr Canc Netw 11:663-6. 2013
    ..He also offered a brief mention of 2 new agents recently approved for resistant CML--ponatinib and bosutinib...
  2. pmc A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia
    Jerald P Radich
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 120:3898-905. 2012
    ..In summary, DAS compared with IM appeared to have more short-term cytogenetic and molecular response, more hematologic toxicity, and similar overall survival. This trial is registered at www.clinicaltrials.gov as NCT00070499...
  3. doi request reprint The biology of chronic myelogenous leukemia progression: who, what, where, and why?
    Jerald P Radich
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Hematol Oncol Clin North Am 25:967-80, v. 2011
    ..Some of the genes and pathways uncovered offer some progress for research on novel therapy for blast crisis...
  4. doi request reprint Measuring response to BCR-ABL inhibitors in chronic myeloid leukemia
    Jerald P Radich
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Cancer 118:300-11. 2012
    ..The deepest measure of response-a complete molecular response-may help identify patients who can stop taking imatinib for the short term, although the long-term consequences of this strategy remain unknown...
  5. doi request reprint Chronic myeloid leukemia 2010: where are we now and where can we go?
    Jerald P Radich
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Hematology Am Soc Hematol Educ Program 2010:122-8. 2010
    ....
  6. ncbi request reprint HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen
    Jerald P Radich
    Clinical Research Division, Fred Hutchinson Cancer Research Center, D4 100, 1100 Fairview Ave N, Seattle, WA 98109, USA
    Blood 102:31-5. 2003
    ..6 copies/microg RNA. These data suggest that TBU/CY is a very effective preparative regimen for CML in chronic phase, associated with an expected survival at 3 years of approximately 85%, with most patients being in molecular remission...
  7. pmc Gene expression changes associated with progression and response in chronic myeloid leukemia
    Jerald P Radich
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Proc Natl Acad Sci U S A 103:2794-9. 2006
    ..These studies point to specific gene pathways that might be exploited for both prognostic indicators as well as new targets for therapy...
  8. ncbi request reprint Individual-specific variation of gene expression in peripheral blood leukocytes
    Jerald P Radich
    Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, D4 100, Seattle, WA 98109, USA
    Genomics 83:980-8. 2004
    ..These studies demonstrate the feasibility of using DNA microarrays to measure the variations in gene expression of PBL from different individuals in response to environmental and genetic factors...
  9. ncbi request reprint Monitoring chronic myelogenous leukemia in the age of tyrosine kinase inhibitors
    Jerald P Radich
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, Seattle, WA 98109, USA
    J Natl Compr Canc Netw 5:497-504. 2007
    ..Fortunately, monitoring CML using cytogenetic and molecular methods (i.e., quantitative polymerase chain reaction) effectively defines end points that correlate highly with outcome...
  10. doi request reprint Molecular monitoring of patients with chronic myeloid leukemia: clinical examples from a non-trial setting
    Jerald P Radich
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Clin Lymphoma Myeloma 9:S391-4. 2009
    ..This review will examine the use of molecular monitoring in the non-trial setting, concentrating on pitfalls that can occur in the real-world delivery of complex medical care...
  11. doi request reprint Optimizing timing of secondary tyrosine kinase therapy in chronic myeloid leukemia
    Jerald P Radich
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Clin Lymphoma Myeloma 8:S89-94. 2008
    ..This review will define the types of tests used to monitor the disease, provide clinically relevant endpoints, and outline guidelines for monitoring patients with CML on imatinib therapy...
  12. pmc Stem cell transplant for chronic myeloid leukemia in the imatinib era
    Jerald Radich
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Semin Hematol 47:354-61. 2010
    ..This article reviews the data on the variables that influence outcome following transplantation, and discusses the variables to consider in determining which patients should receive transplantation and when...
  13. ncbi request reprint The promise of gene expression analysis in hematopoetic malignancies
    Jerald P Radich
    Clinical Research Division, Program in Genetics and Genomics, Fred Hutchinson Cancer Research Center, D4 100, 1100 Fairview Ave N, Seattle, WA 98109, USA
    Biochim Biophys Acta 1602:88-95. 2002
  14. pmc Solving the mystery of myelodysplasia
    Jerald Radich
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    PLoS Med 5:e40. 2008
  15. ncbi request reprint Clinical applicability of the evaluation of minimal residual disease in acute leukemia
    J P Radich
    Program in Genetics, Clinical Research Division, Seattle, Washington 98109 1024, USA
    Curr Opin Oncol 12:36-40. 2000
    ..We await trials testing the intervention of "molecular relapse." Data appear to be sufficient to launch such trials in diseases such as pediatric acute lymphoblastic leukemia and the t(1 5;1 7) acute myeloid leukemia...
  16. ncbi request reprint Second allogeneic transplantation after failure of first autologous transplantation
    J P Radich
    Clinical Research Division of the Fred Hutchinson Cancer Research Center University of Washington School of Medicine, 98109, USA
    Biol Blood Marrow Transplant 6:272-9. 2000
    ..Alternative experimental strategies, such as low-dose nonmyeloablative allogeneic minitransplantations, should be considered...
  17. ncbi request reprint Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia
    Jerald P Radich
    Clinical Research Division, Fred Hutchinson Cancer Research Center, D4 100, 1100 Fairview Avenue North, Seattle, WA 98109, USA
    Hematol Oncol Clin North Am 18:685-702, x. 2004
    ..Similarly,patients who fail to respond to imatinib should be rescued with a transplant strategy. The role of molecular monitoring in these two strategies cannot be underestimated...
  18. ncbi request reprint The detection and significance of minimal residual disease in chronic myeloid leukemia
    J P Radich
    Clinical Research Division, Program in Genetics and Genomics, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, D4 100, P O Box 19024, Seattle, WA 98109 1024, USA
    Medicina (B Aires) 60:66-70. 2000
    ..In addition, the promise of genomics offers hope that in the near future, leukemia may be sub-classified by the genetic profile of an individual patient's particular leukemia, allowing truly "tailored" individual therapy...
  19. ncbi request reprint New developments in the treatment of acute myeloid leukemia
    J Radich
    Clinical Research Division, Program in Genetics and Genomics, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    Oncology (Williston Park) 14:125-31. 2000
    ..With this technology, we may determine the genes responsible for the biological properties of treatment response and relapse in leukemia patients...
  20. ncbi request reprint The use of PCR technology for detecting minimal residual disease in patients with leukemia
    J P Radich
    Fred Hutchinson Cancer Research Center, Seattle, USA 98109 1024, USA
    Rev Immunogenet 1:265-78. 1999
    ..The study of MRD is thus evolving from identifying patients at high risk of relapse to explaining how leukemia can persist for years in an otherwise "cured" patient...
  21. ncbi request reprint Philadelphia chromosome-positive acute lymphocytic leukemia
    J P Radich
    Clinical Research Division, Program in Genetics and Genomics, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    Hematol Oncol Clin North Am 15:21-36. 2001
    ..For those without a donor, following the disease by PCR-based techniques may detect early relapse. For relapsed patients without the option of transplantation, investigative studies are appropriate...
  22. ncbi request reprint The significance of bcr-abl molecular detection in chronic myeloid leukemia patients "late," 18 months or more after transplantation
    J P Radich
    Clinical Research Division, Fred Hutchinson Cancer Research Center, The University of Washington School of Medicine, Seattle, WA, USA
    Blood 98:1701-7. 2001
    ..The detection of bcr-abl is common following transplantation. The prognostic significance of a qualitative bcr-abl can be refined by quantitative assays and thus may target patients who would benefit from early intervention...
  23. pmc How I monitor residual disease in chronic myeloid leukemia
    Jerald P Radich
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 114:3376-81. 2009
    ..This article will try to address these issues by describing how I monitor CML, which, in summary, is with interest and without panic...
  24. ncbi request reprint Maintenance therapy with tyrosine kinase inhibitors after transplant in patients with chronic myeloid leukemia
    Merav Bar
    From the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    J Natl Compr Canc Netw 11:308-15. 2013
    ..Molecular monitoring of the BCR-ABL chimeric mRNA posttransplant is important for early detection of patients at high risk of relapse...
  25. ncbi request reprint Limits of HLA mismatching in unrelated hematopoietic cell transplantation
    Effie W Petersdorf
    Division of Clinical Research, D4 100 Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA 98109, USA
    Blood 104:2976-80. 2004
    ..Whenever possible, HLA-C mismatches should be avoided for patients with early stage CML, and HLA-DQB1 mismatches should be avoided for patients with multiple mismatches...
  26. ncbi request reprint Increased AF1q gene expression in high-risk myelodysplastic syndrome
    William Tse
    Clinical Research Division, Fred Hutchinson Cancer Research Center, and Department of Medicine, University of Washington School of Medicine, Seattle, WA 98109, USA
    Br J Haematol 128:218-20. 2005
    ..05). Among IPSS high-risk patients, survival correlated inversely with AF1q levels (P = 0.04). Thus, AF1q levels correlate with high-risk MDS and may provide a marker for risk stratification...
  27. ncbi request reprint Allogeneic hematopoietic stem cell transplantation for myelofibrosis
    H Joachim Deeg
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D1 100, PO Box 19024, Seattle, WA 98109 1024, USA
    Blood 102:3912-8. 2003
    ..Results with unrelated donors were comparable with those with HLA-identical sibling transplants. Thus, allogeneic hematopoietic cell transplantation offers long-term relapse-free survival for patients with myelofibrosis...
  28. pmc Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning
    Mohamed L Sorror
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    J Clin Oncol 26:4912-20. 2008
    ..Here, we have extended the follow-up to a median of 5 years and have included data on an additional 18 patients...
  29. ncbi request reprint A distinctive nuclear morphology in acute myeloid leukemia is strongly associated with loss of HLA-DR expression and FLT3 internal tandem duplication
    S J Kussick
    Department of Laboratory Medicine, University of Washington, Seattle, WA, USA
    Leukemia 18:1591-8. 2004
    ....
  30. ncbi request reprint Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia
    S Meshinchi
    The Fred Hutchinson Cancer Research Center, and University of Washington Medical Center, Seattle, WA 98103, USA
    Blood 97:89-94. 2001
    ..002). Multivariate analysis demonstrated that presence of the Flt3/ITD was the single most significant, independent prognostic factor for poor outcome (P =.009) in pediatric AML...
  31. ncbi request reprint FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia
    D L Stirewalt
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA 98109, USA
    Blood 97:3589-95. 2001
    ..Blood. 2001;97:3589-3595)..
  32. ncbi request reprint Quantitative, real-time polymerase chain reactions for FLT3 internal tandem duplications are highly sensitive and specific
    D L Stirewalt
    Program in Genetics and Genomics, Clinical Research Division, Fred Hutchinson Cancer Research Center, D4 100, 1100 Fairview Avenue North, Seattle, WA 98109, USA
    Leuk Res 25:1085-8. 2001
    ..01 and 0.001% of FLT3 ITD positive DNA in a background of 1 microg of normal bone marrow DNA. Our findings suggest that FLT3 ITDs can be used as molecular markers for MRD in patients with AML...
  33. ncbi request reprint Comparison of multidimensional flow cytometry with standard morphology for evaluation of early marrow response in pediatric acute lymphoblastic leukemia
    S Meshinchi
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    J Pediatr Hematol Oncol 23:585-90. 2001
    ..We compared multidimensional flow cytometry (MDF) with morphology in evaluating early marrow response to induction chemotherapy in pediatric ALL...
  34. pmc Gene expression patterns in myelodyplasia underline the role of apoptosis and differentiation in disease initiation and progression
    Merav Bar
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington
    Transl Oncogenomics 3:137-49. 2008
    ..Taken together with previous published data, the present results also underscore the considerable complexity of the regulation of gene expression in MDS...
  35. ncbi request reprint End points to establish the efficacy of new agents in the treatment of acute leukemia
    Frederick R Appelbaum
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 109:1810-6. 2007
    ..In this report, we present the results of that effort...
  36. ncbi request reprint The case for early detection
    Ruth Etzioni
    Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, Washington 98109, USA
    Nat Rev Cancer 3:243-52. 2003
    ..been revitalized by the advent of novel molecular technologies that can identify cellular changes at the level of the genome or proteome, but how can we harness these new technologies to develop effective and practical screening tests?..
  37. ncbi request reprint p73 mutations and expression in adult de novo acute myelogenous leukemia
    D L Stirewalt
    Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington, Seattle 98109, USA
    Leukemia 13:985-90. 1999
    ..In addition, biallelic expression of p73 occurs in normal bone marrows, some AML samples, and specific cell lines. Lastly, monoallelic p73 expression appears to be common in de novo AML...
  38. ncbi request reprint The detection and significance of minimal residual disease in acute and chronic leukemia
    N G Chung
    Clinical Research Division, Program in Genetics and Genomics, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Tissue Antigens 68:371-85. 2006
    ..These assays are now increasingly used in clinical trial design to optimize therapy and provide a novel way to assess treatment efficacy...
  39. pmc Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study
    P A Ho
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Leukemia 24:909-13. 2010
    ..Eleven patients (2.1%) harbored a novel V71I sequence alteration, which was found to be a germ-line polymorphism. IDH1 mutations were not detected in pediatric AML, and are uncommon in adult AML...
  40. pmc Proteomic classification of acute leukemias by alignment-based quantitation of LC-MS/MS data sets
    Eric J Foss
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, United States
    J Proteome Res 11:5005-10. 2012
    ....
  41. ncbi request reprint Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML
    F R Kerbauy
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Leukemia 19:990-7. 2005
    ..The 2-year survival estimates for patients in CP1 (n=14) and beyond CP1 (n=10) were 70 and 56%, respectively. This study shows encouraging remission rates for patients with CML not eligible for conventional allografting...
  42. ncbi request reprint Molecular measurement of minimal residual disease in Philadelphia-positive acute lymphoblastic leukaemia
    Jerald P Radich
    Clinical Research Division, Program in Genetics and Genomics, Fred Hutchinson Cancer Research Center, D4 100 1100 Fairview Avenue, North Seattle, WA 98109, USA
    Best Pract Res Clin Haematol 15:91-103. 2002
    ..With the advent of novel therapeutics that target the structure and function of BCR-ABL, the detection of MRD may allow for targeted therapy that could abort a potential relapse...
  43. ncbi request reprint Molecular classification of acute myeloid leukemia: are we there yet?
    Jerald P Radich
    J Clin Oncol 26:4539-41. 2008
  44. pmc Structural and numerical variation of FLT3/ITD in pediatric AML
    Soheil Meshinchi
    Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington Medical Center, Seattle, USA
    Blood 111:4930-3. 2008
    ..035), while the presence of more than 1 ITD was not clinically significant. Physical characteristics including the length of FLT3/ITD may influence FLT3 activation state by altering its structure and may impact response to therapy...
  45. ncbi request reprint Progenitor cell involvement is predictive of response to induction chemotherapy in paediatric acute myeloid leukaemia
    Donna L Johnston
    Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Br J Haematol 123:431-5. 2003
    ..However, five of six evaluable patients with colonies negative for monosomy 7 entered remission. These data support the hypothesis that leukaemic involvement of early progenitor cells affects the response to induction chemotherapy...
  46. ncbi request reprint Tumour necrosis factor-induced gene expression in human marrow stroma: clues to the pathophysiology of MDS?
    Derek L Stirewalt
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Br J Haematol 140:444-53. 2008
    ..Additional studies will be required to determine which of these signals are critical for the induction of apoptosis in the malignant clones. Those insights, in turn, may point the way to novel therapeutic approaches...
  47. ncbi request reprint Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia
    Philipp Le Coutre
    Campus Virchow Klinikum, Charite Universitatsmedizin, Berlin, Germany
    Blood 111:1834-9. 2008
    ..In conclusion, nilotinib is an effective and well-tolerated treatment in imatinib-resistant and -intolerant CML-AP. This trial is registered at www.clinicaltrials.gov as NCT00384228...
  48. ncbi request reprint Identification of genes with abnormal expression changes in acute myeloid leukemia
    Derek L Stirewalt
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Genes Chromosomes Cancer 47:8-20. 2008
    ..Future studies will determine their potential role in leukemogenesis and their clinical significance...
  49. ncbi request reprint Survival after second hematopoietic stem cell transplantation for recurrent pediatric acute myeloid leukemia
    Soheil Meshinchi
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Biol Blood Marrow Transplant 9:706-13. 2003
    ..Because a higher tumor burden at the time of second HSCT was associated with a higher risk of subsequent relapse, patients might benefit from reinduction therapy before the second HSCT...
  50. ncbi request reprint Single-stranded linear amplification protocol results in reproducible and reliable microarray data from nanogram amounts of starting RNA
    Derek L Stirewalt
    Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98109, USA
    Genomics 83:321-31. 2004
    ..05 microg. These results suggest that SLAP is an excellent alternative to IVT-based amplification protocols when RNA is limited by small sample size...
  51. ncbi request reprint Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia
    Tim P Hughes
    Institute of Medical and Veterinary Science, Adelaide, SA, Australia
    N Engl J Med 349:1423-32. 2003
    ..We measured levels of BCR-ABL transcripts in the blood of all patients in this trial who had a complete cytogenetic remission...
  52. ncbi request reprint The role of FLT3 in haematopoietic malignancies
    Derek L Stirewalt
    Clinical Research Division, Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA 98109, USA
    Nat Rev Cancer 3:650-65. 2003
    ..Exploring the mechanism by which these FLT3 mutations cause uncontrolled proliferation might lead to a better understanding of how cells become cancerous and provide insights for the development of new drugs...
  53. ncbi request reprint Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia
    Mohamed L Sorror
    Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, D1 100, PO Box 19024, Seattle, WA 98109 1024, USA
    J Clin Oncol 23:3819-29. 2005
    ..The aim of this study was to analyze the outcome of patients with advanced CLL when treated with nonmyeloablative conditioning and hematopoietic cell transplantation (HCT)...
  54. ncbi request reprint Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome
    H Joachim Deeg
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 100:1201-7. 2002
    ..Although there was still considerable nonrelapse morbidity and mortality, the present regimen was used successfully even in patients older than 60 years of age...
  55. ncbi request reprint Curative therapy of advanced essential thrombocythemia or polycythemia vera by hemopoietic stem cell transplantation
    Uwe Platzbecker
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Leuk Lymphoma 43:1409-14. 2002
    ..With a median follow-up of 41 (range 5-116) months after transplant, survival at 3 years is 64%. These data provide evidence that HSCT can be a curative treatment for patients with advanced PV and ET...
  56. ncbi request reprint Related and unrelated nonmyeloablative hematopoietic stem cell transplantation for malignant diseases
    George E Georges
    Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, USA
    Int J Hematol 76:184-9. 2002
    ..Related and unrelated nonmyeloablative HSCT is feasible and potentially curative in patients with advanced hematological malignancies who have no other treatment options...
  57. ncbi request reprint Molecular targets in acute myelogenous leukemia
    Derek L Stirewalt
    Clinical Research Division, Fred Hutchinson Cancer Research Center, The Division of Oncology, University of Washington, Seattle 98109, USA
    Blood Rev 17:15-23. 2003
    ..After reviewing these two pathways, we explore some of the targeted therapies directed at these pathways that are under development for AML, many of which are already in clinical trials...
  58. ncbi request reprint Predictors of relapse and overall survival in Philadelphia chromosome-positive acute lymphoblastic leukemia after transplantation
    Derek L Stirewalt
    Fred Hutchinson Cancer Research Center, Division of Oncology, University of Washington, Seattle, Washington 98109, USA
    Biol Blood Marrow Transplant 9:206-12. 2003
    ....
  59. ncbi request reprint Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia
    Soheil Meshinchi
    Fred Hutchinson Cancer Research Center, Division of Clinical Research, D4 100, 1100 Fairview Ave N, PO Box 19024, Seattle, WA 98109 1024, USA
    Blood 102:1474-9. 2003
    ..38). Activating mutations in the RTK/ras signaling pathway are common in pediatric AML, and their presence may identify a population at higher risk of poor outcome who may benefit from allogeneic BM transplantation...
  60. ncbi request reprint FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance
    Christian M Zwaan
    Department of Pediatric Hematology Oncology, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    Blood 102:2387-94. 2003
    ..However, poor outcomes in FLT3/ITD-positive patients could not be attributed to increased in vitro cellular drug resistance...
  61. ncbi request reprint Monitoring bcr-abl by polymerase chain reaction in the treatment of chronic myeloid leukemia
    Vivian G Oehler
    Clinical Research Division, Program in Genetics and Genomics, Fred Hutchinson Cancer Research Center, D4 100, 1100 Fairview Avenue North, Seattle, WA 98109, USA
    Curr Oncol Rep 5:426-35. 2003
    ..This review focuses primarily on MRD monitoring by PCR...
  62. ncbi request reprint Chronic myelogenous leukemia
    Susan O'Brien
    University of Texas M D Anderson Cancer Center, USA
    J Natl Compr Canc Netw 5:474-96. 2007
  63. ncbi request reprint Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen
    H Joachim Deeg
    Fred Hutchinson Cancer Research Center and University of Washington School of Medicine, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 12:573-84. 2006
    ....
  64. ncbi request reprint Role of allogeneic stem cell transplantation in FLT3/ITD-positive AML
    Soheil Meshinchi
    Blood 108:400; author reply 400-1. 2006
  65. ncbi request reprint Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes
    Norman J Lacayo
    Division of Pediatric Hematology Oncology, Stanford University School of Medicine, Palo Alto, CA, USA
    Blood 104:2646-54. 2004
    ..0001). Thus, gene expression profiling identified AML patients with divergent prognoses within the FLT3-MU group, and the RUNX3 to ATRX expression ratio should be a useful prognostic indicator in these patients...
  66. ncbi request reprint Evidence of donor-derived hematologic malignancies after hematopoietic stem cell transplantation
    Olga Sala-Torra
    Division of Clinical Research, Program in Genetics and Genomics, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Biol Blood Marrow Transplant 12:511-7. 2006
    ..Donors in the first group were significantly older than donors in the second group. A more systematic examination of the prevalence and biology of donor malignancies would merit study...
  67. pmc Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction
    Carla S Wilson
    Department of Pathology, University of New Mexico UNM, Albuquerque, 87131, USA
    Blood 108:685-96. 2006
    ..These gene expression signatures provide insights into novel groups of AML not predicted by traditional studies that impact prognosis and potential therapy...
  68. ncbi request reprint Elevated expression of the AF1q gene, an MLL fusion partner, is an independent adverse prognostic factor in pediatric acute myeloid leukemia
    William Tse
    Fred Hutchinson Cancer Research Center, Department of Medicine, University of Washington School of Medicine, Seattle, USA
    Blood 104:3058-63. 2004
    ..01). AF1q expression may correlate with clinical outcome in pediatric AML, although it is not clear if AF1q is simply a marker of a more primitive phenotype or contributes directly to leukemogenesis...
  69. pmc Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia
    Derek L Stirewalt
    Fred Hutchinson Cancer Research Center, D5 380, 1100 Fairview Ave N Seattle, WA 98109, USA
    Blood 107:3724-6. 2006
    ..072) and RFS (estimated 5-year RFS: large = 13%, small = 27%, and no ITD = 34%, P = .017). These studies suggest that ITD size may have prognostic significance...
  70. ncbi request reprint Chronic myelogenous leukemia
    Susan O'Brien
    J Natl Compr Canc Netw 3:732-55. 2005
  71. ncbi request reprint HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemia
    Frederic Baron
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 11:272-9. 2005
    ..Further efforts are directed at reducing the risk of graft rejection by exclusive use of G-PBMC and increasing the degree of pretransplantation immunosuppression...
  72. ncbi request reprint Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning
    Frederic Baron
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D1 100, PO Box 19024, Seattle, WA 98109 1024, USA
    Blood 104:2254-62. 2004
    ..02). Measuring the levels of peripheral blood cell subset donor chimerisms provided useful information on HCT outcomes and might allow early therapeutic interventions to prevent graft rejection or disease progression...
  73. ncbi request reprint Methylenetetrahydrofolate reductase genotype affects risk of relapse after hematopoietic cell transplantation for chronic myelogenous leukemia
    Kim Robien
    Cancer Prevention Program, Public Health Sciences Division and Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Clin Cancer Res 10:7592-8. 2004
    ..We evaluated the association of these polymorphisms with risk of relapse and bcr-abl mRNA transcript detection among 336 Caucasian patients who underwent allogeneic hematopoietic cell transplantation for chronic myelogenous leukemia...
  74. pmc FLT3 internal tandem duplication in CD34+/CD33- precursors predicts poor outcome in acute myeloid leukemia
    Jessica A Pollard
    Fred Hutchinson Cancer Research Center, Clinical Research Division, D2 373, 1100 Fairview Ave N, Seattle, WA 98109, USA
    Blood 108:2764-9. 2006
    ..002). This study suggests that FLT3/ITD involvement in CD34(+)/CD33(-) precursors is heterogeneous and that detection of the mutation in the less-mature progenitor population may be associated with disease resistance...
  75. pmc Connective tissue growth factor (CTGF) expression and outcome in adult patients with acute lymphoblastic leukemia
    Olga Sala-Torra
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Blood 109:3080-3. 2007
    ..36, for each 10-fold increase in expression; P = .019). Further studies are ongoing to confirm the prognostic value of CTGF expression in ALL and to investigate its role in normal and abnormal lymphocyte biology...
  76. ncbi request reprint Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
    Brian J Druker
    Oregon Health and Science University Cancer Institute, L592, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA
    N Engl J Med 355:2408-17. 2006
    ..Imatinib inhibits this kinase, and in a short-term study was superior to interferon alfa plus cytarabine for newly diagnosed CML in the chronic phase. For 5 years, we followed patients with CML who received imatinib as initial therapy...
  77. pmc Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia
    Paul A Carpenter
    Clinical Research Division, Fred Hutchinson Cancer Research Center FHCRC, Seattle, WA 98109, USA
    Blood 109:2791-3. 2007
    ..We conclude that imatinib can be safely administered early after myeloablative allogeneic HCT at a dose intensity comparable to that used in primary therapy...
  78. ncbi request reprint Novel FLT3 point mutations within exon 14 found in patients with acute myeloid leukaemia
    Derek L Stirewalt
    Clinical Research Division, Fred Hutchinson Cancer Research Center, and Division of Oncology, University of Washington, Seattle, WA 98109, USA
    Br J Haematol 124:481-4. 2004
    ..Novel missense point mutations were found in exon 14, suggesting additional investigations should be performed in AML and other haematopoietic malignancies, using this sensitive technique...
  79. ncbi request reprint Signatures of environmental exposures using peripheral leukocyte gene expression: tobacco smoke
    Johanna W Lampe
    Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Cancer Epidemiol Biomarkers Prev 13:445-53. 2004
    ..These findings suggest that expression patterns can be used to identify a complex environmental exposure in humans...
  80. pmc The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia
    Vivian G Oehler
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 109:1782-9. 2007
    ..However, patients with a suboptimal or loss of IM response before HCT do worse, suggesting a more aggressive disease course for these patients...
  81. ncbi request reprint Use of gene expression microarrays for the study of acute leukemia
    Mar Bellido
    Fred Hutchinson Cancer Research Center, Clinical Research Division, Public Health Sciences Division, 1100 Fairview Ave N, Seattle, WA 98109, USA
    Expert Rev Mol Diagn 6:733-47. 2006
    ..This technology has revolutionized the study of leukemia, giving insight into genes and pathways involved in disease response and the biology involved in specific translocations...
  82. ncbi request reprint Fanconi anemia type C-deficient hematopoietic cells are resistant to TRAIL (TNF-related apoptosis-inducing ligand)-induced cleavage of pro-caspase-8
    Uwe Platzbecker
    University Hospital Carl Gustav Carus, Dresden, Germany
    Exp Hematol 32:815-21. 2004
    ..We investigated whether a new member of the TNF family, TRAIL (TNF-related apoptosis-inducing ligand), would similarly trigger preferential apoptotic cell death in FA phenotype cells...
  83. pmc Clinical implications of FLT3 mutations in pediatric AML
    Soheil Meshinchi
    Fred Hutchinson Cancer Research Center, Clinical Research Division, D5 380, 1100 Fairview Ave N, Seattle, WA 98103, USA
    Blood 108:3654-61. 2006
    ..001) or with FLT3/WT (55%, P < .001). ITD-AR defines the prognostic significance in FLT3/ITD-positive AML, and ITD-AR greater than 0.4 is a significant and independent prognostic factor for relapse in pediatric AML...
  84. ncbi request reprint Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia
    Vivian G Oehler
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Biol Blood Marrow Transplant 11:85-92. 2005
    ..10) and a higher cumulative incidence of chronic GVHD in PBSC recipients (59% versus 40%; P = .11). The trend toward a higher relapse incidence in BM recipients persisted with a longer follow-up...
  85. ncbi request reprint Monitoring patients with chronic myeloid leukemia receiving Abl tyrosine kinase inhibitor therapy
    Vivian Oehler
    Clinical Research Division, Program in Genetics and Genomics, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Clin Lymphoma Myeloma 7:S58-63. 2007
    ..In this review, we define the types of tests used to monitor the disease, provide clinically relevant endpoints, and outline guidelines for monitoring patients with CML receiving imatinib therapy...
  86. doi request reprint Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials
    Susan Branford
    Institute of Medical and Veterinary Science, Adelaide, Australia
    Blood 112:3330-8. 2008
    ..This indicates that the IS can deliver accurate comparison of molecular response rates between clinical trials when measured by different laboratories...
  87. pmc DDX3Y encodes a class I MHC-restricted H-Y antigen that is expressed in leukemic stem cells
    Kellie V Rosinski
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 111:4817-26. 2008
    ..This study is registered at http://clinicaltrials.gov as NCT00107354...
  88. ncbi request reprint Development of an integrated assay for detection of BCR-ABL RNA
    Emily S Winn-Deen
    Cepheid, Sunnyvale, CA, USA
    Clin Chem 53:1593-600. 2007
    ....